Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The supplements are made using only vegetarian-sourced ingredients
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated